Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment
- 10 April 2018
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (11), 1121-1127
- https://doi.org/10.1200/jco.2017.75.2501
Abstract
High-deductible health plans (HDHPs) require substantial out-of-pocket spending and might delay crucial health services. Breast cancer treatment delays of as little as 2 months are associated with adverse outcomes. We used a controlled prepost design with survival analysis to assess timing of breast cancer care events among 273,499 women age 25 to 64 years without evidence of breast cancer before inclusion. Women were included if continuously enrolled for 1 year in a low-deductible ($0 to $500) plan followed by up to 4 years in a HDHP (at least $1,000 deductible) after an employer-mandated switch. Study inclusion was on a rolling basis, and members were followed between 2003 and 2012. The comparison group comprised 2.4 million contemporaneously matched women whose employers offered only low-deductible plans. Measures were times to first diagnostic breast imaging (diagnostic mammogram, breast ultrasound, or breast magnetic resonance imaging), breast biopsy, incident early-stage breast cancer diagnosis, and breast cancer chemotherapy. Outcomes were analyzed by using Cox models and adjusted for age-group, morbidity score, poverty level, US region, index date, and employer size. After the index date, HDHP members experienced delays in receipt of diagnostic imaging (adjusted hazard ratio [aHR], 0.95; 95% CI, 0.94 to 0.96), biopsy (aHR, 0.92; 95% CI, 0.89 to 0.95), early-stage breast cancer diagnosis (aHR, 0.83; 0.78 to 0.90), and chemotherapy initiation (aHR, 0.79; 95% CI, 0.72 to 0.86) compared with the control group. Women switched to HDHPs experienced delays in diagnostic breast imaging, breast biopsy, early-stage breast cancer diagnosis, and chemotherapy initiation. Additional research should determine whether such delays cause adverse health outcomes, and policymakers should consider selectively reducing out-of-pocket costs for key breast cancer services.This publication has 33 references indexed in Scilit:
- Out‐of‐pocket health care expenditure burden for Medicare beneficiaries with cancerCancer, 2012
- Causal Inference without Balance Checking: Coarsened Exact MatchingPolitical Analysis, 2012
- Association Between Prescription Co-Payment Amount and Compliance With Adjuvant Hormonal Therapy in Women With Early-Stage Breast CancerJournal of Clinical Oncology, 2011
- Multivariate Matching Methods That Are Monotonic Imbalance BoundingJournal of the American Statistical Association, 2011
- Impact of interval from breast conserving surgery to radiotherapy on local recurrence in older women with breast cancer: retrospective cohort analysisBMJ, 2010
- Costs and quality of hospitals in different health care systems: a multi-level approach with propensity score matchingHealth Economics, 2010
- The Effect Of Consumer-Directed Health Plans On The Use Of Preventive And Chronic Illness ServicesHealth Affairs, 2008
- Effects Of A Cost-Sharing Exemption On Use Of Preventive Services At One Large EmployerHealth Affairs, 2006
- Use of Geocoding and Surname Analysis to Estimate Race and EthnicityHealth Services Research, 2006
- PENSIVE WOMEN, PAINFUL VIGILS: CONSEQUENCES OF DELAY IN ASSESSMENT OF MAMMOGRAPHIC ABNORMALITIESThe Lancet, 1988